Last reviewed · How we verify
NCT03706534
Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms
NA trial testing Ultrasound Image review with CADe in Breast Cancer in 300 participants. Status unknown.
30 November 2019
Quick facts
| Lead sponsor | Samsung Medison |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | device feasibility |
| Enrollment | 300 |
| Start date | 20 September 2018 |
| Primary completion | 30 November 2019 |
| Estimated completion | 31 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ultrasound Image review with CADe
- Ultrasound Image review with CADx
- Ultrasound Image manual review
- Biopsy — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Lesions — all drugs for Breast Lesions →
- Breast Mass — all drugs for Breast Mass →
Sponsor
Samsung Medison
Who can join
19 and older, any sex, with Breast Cancer or Breast Lesions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates a second review of ultrasound images of breast lesions using an interactive "deep learning" (or artificial intelligence) program developed by Samsung Medical Imaging, to see if this artificial intelligence will help the Radiologist make more accurate diagnoses.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies.
Nagendran M, Chen Y, Lovejoy CA, Gordon AC, et al · · 2020 · cited 603× · PMID 32213531 · DOI 10.1136/bmj.m689 -
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.
Jiang B, Bao L, He S, Chen X, et al · · 2024 · cited 36× · PMID 39304962 · DOI 10.1186/s13058-024-01895-6
Verify or expand the search:
- PubMed search for NCT03706534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03706534 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medison
- Last refreshed: 29 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03706534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing